Clinical validation of genetic variants associated with in vitro chemotherapy-related lymphoblastoid cell toxicity
Hematotoxicity is one of the major side effects of chemotherapy. The aim of this study was to examine the association between single nucleotide polymorphisms (SNPs) and hematotoxicity in breast cancer patients in a subset of patients of the SUCCESS prospective phase III chemotherapy study. All patie...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
May 09, 2017
|
| In: |
OncoTarget
Year: 2017, Volume: 8, Issue: 44, Pages: 78133-78143 |
| ISSN: | 1949-2553 |
| DOI: | 10.18632/oncotarget.17726 |
| Online Access: | Verlag, Volltext: http://dx.doi.org/10.18632/oncotarget.17726
|
| Author Notes: | Peter A. Fasching, Lothar Häberle, Brigitte Rack, Liang Li, Alexander Hein, Arif B. Ekici, Andre Reis, Michael P. Lux, Julie M. Cunningham, Matthias Ruebner, Gergory Jenkins, Brooke Fridley, Andreas Schneeweiss, Hans Tesch, Werner Lichtenegger, Tanja Fehm, Georg Heinrich, Mahdi Rezai, Matthias W. Beckmann, Wolfgang Janni, Richard M. Weinshilboum and Liewei Wang |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1582369275 | ||
| 003 | DE-627 | ||
| 005 | 20230427193212.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 181029s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.18632/oncotarget.17726 |2 doi | |
| 035 | |a (DE-627)1582369275 | ||
| 035 | |a (DE-576)512369275 | ||
| 035 | |a (DE-599)BSZ512369275 | ||
| 035 | |a (OCoLC)1341021967 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Fasching, Peter Andreas |d 1975- |e VerfasserIn |0 (DE-588)129068780 |0 (DE-627)388703040 |0 (DE-576)297477099 |4 aut | |
| 245 | 1 | 0 | |a Clinical validation of genetic variants associated with in vitro chemotherapy-related lymphoblastoid cell toxicity |c Peter A. Fasching, Lothar Häberle, Brigitte Rack, Liang Li, Alexander Hein, Arif B. Ekici, Andre Reis, Michael P. Lux, Julie M. Cunningham, Matthias Ruebner, Gergory Jenkins, Brooke Fridley, Andreas Schneeweiss, Hans Tesch, Werner Lichtenegger, Tanja Fehm, Georg Heinrich, Mahdi Rezai, Matthias W. Beckmann, Wolfgang Janni, Richard M. Weinshilboum and Liewei Wang |
| 264 | 1 | |c May 09, 2017 | |
| 300 | |a 11 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 29.10.2018 | ||
| 520 | |a Hematotoxicity is one of the major side effects of chemotherapy. The aim of this study was to examine the association between single nucleotide polymorphisms (SNPs) and hematotoxicity in breast cancer patients in a subset of patients of the SUCCESS prospective phase III chemotherapy study. All patients (n = 1678) received three cycles of 5-fluorouracil, epirubicin, and cyclophosphamide (FEC) followed by three cycles of docetaxel or docetaxel/gemcitabine, depending on randomization. Germline DNA was genotyped for 246 SNPs selected from a previous genome-wide association study (GWAS) in a panel of lymphoblastoid cell lines, with gemcitabine toxicity as the phenotype. All SNPs were tested for their value in predicting grade 3 or 4 neutropenic or leukopenic events (NLEs). Their prognostic value in relation to overall survival and disease-free survival was also tested. None of the SNPs was found to be predictive for NLEs during treatment with docetaxel/gemcitabine. Two SNPs in and close to the PIGB gene significantly improved the prediction of NLEs after FEC, in addition to the factors of age and body surface area. The top SNP (rs12050587) had an odds ratio of 1.38 per minor allele (95% confidence interval, 1.17 to 1.62). No associations were identified for predicting disease-free or overall survival. Genetic variance in the PIGB gene may play a role in determining interindividual differences in relation to hematotoxicity after FEC chemotherapy. | ||
| 650 | 4 | |a chemotherapy | |
| 650 | 4 | |a leukopenia | |
| 650 | 4 | |a neutropenia | |
| 650 | 4 | |a polymorphism | |
| 650 | 4 | |a SNP | |
| 700 | 1 | |a Schneeweiss, Andreas |d 1961- |e VerfasserIn |0 (DE-588)109972554 |0 (DE-627)632849630 |0 (DE-576)327251859 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t OncoTarget |d [Erscheinungsort nicht ermittelbar] : Impact Journals LLC, 2010 |g 8(2017), 44, Seite 78133-78143 |h Online-Ressource |w (DE-627)63035975X |w (DE-600)2560162-3 |w (DE-576)325343764 |x 1949-2553 |7 nnas |a Clinical validation of genetic variants associated with in vitro chemotherapy-related lymphoblastoid cell toxicity |
| 773 | 1 | 8 | |g volume:8 |g year:2017 |g number:44 |g pages:78133-78143 |g extent:11 |a Clinical validation of genetic variants associated with in vitro chemotherapy-related lymphoblastoid cell toxicity |
| 856 | 4 | 0 | |u http://dx.doi.org/10.18632/oncotarget.17726 |x Verlag |x Resolving-System |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20181029 | ||
| 993 | |a Article | ||
| 994 | |a 2017 | ||
| 998 | |g 109972554 |a Schneeweiss, Andreas |m 109972554:Schneeweiss, Andreas |d 910000 |d 910400 |e 910000PS109972554 |e 910400PS109972554 |k 0/910000/ |k 1/910000/910400/ |p 13 | ||
| 999 | |a KXP-PPN1582369275 |e 3029948536 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"origin":[{"dateIssuedKey":"2017","dateIssuedDisp":"May 09, 2017"}],"relHost":[{"title":[{"subtitle":"open access impact journal","title":"OncoTarget","title_sort":"OncoTarget"}],"id":{"eki":["63035975X"],"issn":["1949-2553"],"zdb":["2560162-3"]},"physDesc":[{"extent":"Online-Ressource"}],"origin":[{"publisher":"Impact Journals LLC","dateIssuedDisp":"2010-","dateIssuedKey":"2010","publisherPlace":"[Erscheinungsort nicht ermittelbar]"}],"recId":"63035975X","disp":"Clinical validation of genetic variants associated with in vitro chemotherapy-related lymphoblastoid cell toxicityOncoTarget","type":{"bibl":"periodical","media":"Online-Ressource"},"language":["eng"],"part":{"volume":"8","year":"2017","text":"8(2017), 44, Seite 78133-78143","pages":"78133-78143","extent":"11","issue":"44"},"note":["Gesehen am 16.08.2018"],"pubHistory":["1.2010,Mai -"]}],"id":{"eki":["1582369275"],"doi":["10.18632/oncotarget.17726"]},"physDesc":[{"extent":"11 S."}],"title":[{"title":"Clinical validation of genetic variants associated with in vitro chemotherapy-related lymphoblastoid cell toxicity","title_sort":"Clinical validation of genetic variants associated with in vitro chemotherapy-related lymphoblastoid cell toxicity"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"note":["Gesehen am 29.10.2018"],"recId":"1582369275","person":[{"given":"Peter Andreas","display":"Fasching, Peter Andreas","family":"Fasching","role":"aut"},{"display":"Schneeweiss, Andreas","given":"Andreas","role":"aut","family":"Schneeweiss"}],"name":{"displayForm":["Peter A. Fasching, Lothar Häberle, Brigitte Rack, Liang Li, Alexander Hein, Arif B. Ekici, Andre Reis, Michael P. Lux, Julie M. Cunningham, Matthias Ruebner, Gergory Jenkins, Brooke Fridley, Andreas Schneeweiss, Hans Tesch, Werner Lichtenegger, Tanja Fehm, Georg Heinrich, Mahdi Rezai, Matthias W. Beckmann, Wolfgang Janni, Richard M. Weinshilboum and Liewei Wang"]},"language":["eng"]} | ||
| SRT | |a FASCHINGPECLINICALVA0920 | ||